FOLH1 and prostate carcinoma: Recently, the Food and Drug Administration (FDA) approved 68Ga-PSMA as the first PSMA-targeted PET drug in potentially curable patients with suspected prostate cancer metastasis or for patients with suspected cancer recurrence [14].